Recro Pharma – Consensus Indicates Potential 152.5% Upside

Broker Ratings

Recro Pharma with ticker code (REPH) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 10 and 5 with the average target price sitting at 7.5. Now with the previous closing price of 2.97 this would imply there is a potential upside of 152.5%. The 50 day MA is 2.28 and the 200 day MA is 3.02. The market cap for the company is $78m. Visit the company website at: http://www.recropharma.com

Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I and changed its name to Recro Pharma in August 2008. Recro Pharma was founded in 2007 and is based in Malvern, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index